The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines

Several protein vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of protein vaccines. This will help...

Descripción completa

Detalles Bibliográficos
Autores principales: Kochhar, Sonali, Kim, Denny, Excler, Jean-Louis, Condit, Richard C., Robertson, James S., Drew, Stephen, Whelan, Mike, Wood, David, Fast, Patricia E., Gurwith, Marc, Klug, Bettina, Khuri-Bulos, Najwa, Smith, Emily R., Chen, Robert T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343648/
https://www.ncbi.nlm.nih.gov/pubmed/32653276
http://dx.doi.org/10.1016/j.vaccine.2020.06.044
Descripción
Sumario:Several protein vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of protein vaccines. This will help key stakeholders to assess potential safety issues and understand the benefit-risk of such a vaccine platform. The structured and standardized assessment provided by the template would also help contribute to improved public acceptance and communication of licensed protein vaccines.

Ejemplares similares